Transcriptional down-regulation of Bcl-2 by vinorelbine: identification of a novel binding site of p53 on Bcl-2 promoter.
暂无分享,去创建一个
Jean Imbert | Diane Braguer | A. Savry | M. Carré | C. Chacon | D. Braguer | V. Bourgarel-Rey | J. Imbert | Y. Barra | Véronique Bourgarel-Rey | Amandine Savry | Guoqiang Hua | Manon Carré | Céline Bressin | Christine Chacon | Yves Barra | G. Hua | C. Bressin
[1] M. Carré,et al. Microtubules in apoptosis induction: are they necessary? , 2007, Current cancer drug targets.
[2] L. Boxer,et al. The WT1 Protein Is a Negative Regulator of the Normalbcl-2 Allele in t(14;18) Lymphomas* , 1997, The Journal of Biological Chemistry.
[3] M V Chernov,et al. A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. , 1999, Science.
[4] L. Boxer,et al. Induction of bcl-2 expression by phosphorylated CREB proteins during B-cell activation and rescue from apoptosis , 1996, Molecular and cellular biology.
[5] C. Croce,et al. Inactivation of Bcl-2 by phosphorylation. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[6] R. Bold,et al. AKT inhibition is associated with chemosensitisation in the pancreatic cancer cell line MIA-PaCa-2 , 2003, British Journal of Cancer.
[7] T. Fojo,et al. Enhanced microtubule-dependent trafficking and p53 nuclear accumulation by suppression of microtubule dynamics , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[8] M. Bhat,et al. Carboplatin induces apoptotic cell death through downregulation of constitutively active nuclear factor-kappaB in human HPV-18 E6-positive HEp-2 cells. , 2004, Biochemical and biophysical research communications.
[9] Caroline A Heckman,et al. Negative regulation of bcl-2 expression by p53 in hematopoietic cells , 2001, Oncogene.
[10] J C Reed,et al. Mechanisms of apoptosis. , 2000, The American journal of pathology.
[11] D. Braguer,et al. Opposite effects of antimicrotubule agents on c-myc oncogene expression depending on the cell lines used. , 2000, European journal of cancer.
[12] John Calvin Reed,et al. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. , 1994, Oncogene.
[13] A. Kruczynski,et al. Bcl-2 down-regulation and tubulin subtype composition are involved in resistance of ovarian cancer cells to vinflunine , 2006, Molecular Cancer Therapeutics.
[14] E. Sausville,et al. Susceptibility to drug-induced apoptosis correlates with differential modulation of Bad, Bcl-2 and Bcl-xL protein levels , 2000, Cell Death and Differentiation.
[15] G. Campiani,et al. Selective Induction of Apoptosis by the Pyrrolo-1,5-benzoxazepine 7-[{Dimethylcarbamoyl}oxy]-6-(2-naphthyl)pyrrolo-[2,1-d] (1,5)-benzoxazepine (PBOX-6) in Leukemia Cells Occurs via the c-Jun NH2-Terminal Kinase-Dependent Phosphorylation and Inactivation of Bcl-2 and Bcl-XL , 2004, Journal of Pharmacology and Experimental Therapeutics.
[16] Enrica Martinelli,et al. Bcl-2 down-regulation is a novel mechanism of paclitaxel resistance. , 2003, Molecular pharmacology.
[17] T. Sengupta,et al. Taxol- and okadaic acid-induced destabilization of bcl-2 mRNA is associated with decreased binding of proteins to a bcl-2 instability element. , 2003, Biochemical pharmacology.
[18] P. Hersey,et al. Activation of Jun N-terminal kinase is a mediator of vincristine-induced apoptosis of melanoma cells , 2008, Anti-cancer drugs.
[19] S. Bredow,et al. Identification of a novel Bcl-2 promoter region that counteracts in a p53-dependent manner the inhibitory P2 region. , 2007, Gene.
[20] Yigong Shi,et al. Apoptosome: a platform for the activation of initiator caspases , 2007, Cell Death and Differentiation.
[21] I. Barasoain,et al. Comparative effects of taxol and Taxotere on two different human carcinoma cell lines , 1994, Cancer Chemotherapy and Pharmacology.
[22] M. Aapro,et al. Developments in cytotoxic chemotherapy: advances in treatment utilising vinorelbine. , 2001, Critical reviews in oncology/hematology.
[23] L. Boxer,et al. NF-kappaB activates Bcl-2 expression in t(14;18) lymphoma cells. , 2002, Oncogene.
[24] J. Bergerat,et al. Signal transduction pathways of taxanes-induced apoptosis. , 2003, Current medicinal chemistry. Anti-cancer agents.
[25] C. Borner. The Bcl-2 protein family: sensors and checkpoints for life-or-death decisions. , 2003, Molecular immunology.
[26] R. Schneider-Stock,et al. Trichostatin A causes p53 to switch oxidative-damaged colorectal cancer cells from cell cycle arrest into apoptosis , 2007, Journal of cellular and molecular medicine.
[27] S. Joos,et al. The role of Bcl-2 family members in tumorigenesis. , 2004, Biochimica et biophysica acta.
[28] A. Kruczynski,et al. Low concentrations of vinflunine induce apoptosis in human SK-N-SH neuroblastoma cells through a postmitotic G1 arrest and a mitochondrial pathway. , 2004, Molecular pharmacology.
[29] John Calvin Reed,et al. Identification of a p53-dependent negative response element in the bcl-2 gene. , 1994, Cancer research.
[30] M. Cluck,et al. Mechanisms controlling cellular suicide: role of Bcl-2 and caspases , 1998, Cellular and Molecular Life Sciences CMLS.
[31] S. Korsmeyer,et al. Alternative promoters and exons, somatic mutation and deregulation of the Bcl‐2‐Ig fusion gene in lymphoma. , 1988, The EMBO journal.
[32] K. Suzuki,et al. Drug-induced apoptosis and p53, BCL-2 and BAX expression in breast cancer tissues in vivo and in fibroblast cells in vitro. , 1999, Japanese journal of clinical oncology.
[33] N. Banik,et al. Bcl-2 siRNA Augments Taxol Mediated Apoptotic Death in Human Glioblastoma U138MG and U251MG Cells , 2008, Neurochemical Research.
[34] A. Zeiher,et al. Posttranslational Modification of Bcl-2 Facilitates Its Proteasome-Dependent Degradation: Molecular Characterization of the Involved Signaling Pathway , 2000, Molecular and Cellular Biology.
[35] E. Pasquier,et al. Antiangiogenic activity of paclitaxel is associated with its cytostatic effect, mediated by the initiation but not completion of a mitochondrial apoptotic signaling pathway. , 2004, Molecular cancer therapeutics.
[36] M. Jordan,et al. Mechanism of action of antitumor drugs that interact with microtubules and tubulin. , 2002, Current medicinal chemistry. Anti-cancer agents.
[37] John Calvin Reed,et al. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene , 1995, Cell.
[38] L. Boxer,et al. NF-κB activates Bcl-2 expression in t(14;18) lymphoma cells , 2002, Oncogene.
[39] D. Arango,et al. Decrease in c-Myc activity enhances cancer cell sensitivity to vinblastine , 2006, Anti-cancer drugs.
[40] M. V. Vijayakumar,et al. DNA damaging drugs-induced down-regulation of Bcl-2 is essential for induction of apoptosis in high-risk HPV-positive HEp-2 and KB cells. , 2006, Cancer letters.
[41] H. Kovacic,et al. Patupilone-Induced Apoptosis Is Mediated by Mitochondrial Reactive Oxygen Species through Bim Relocalization to Mitochondria , 2008, Molecular Pharmacology.
[42] Huei-Mei Chen,et al. Pi 1 binding sites are negative regulators of bcl-2 expression in pre-B cells , 1995, Molecular and cellular biology.